Abstract 3047
Background
Recent studies indicate that quality of life plays crucial role in cancer patients’ outcome. In order to obtain a more comprehensive view into this option, we applied three different questionnaires, the European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30), the Functional Assessment of Cancer Therapy-general (FACT-G) and the generic Short –Form 36 (SF-36) for registering the haematological malignancies patients’ point of view.
Methods
A cross- sectional study was established involving 67 patients, treated in a large hospital in a major Northern Greek city, with haematological malignancies undergoing chemotherapy in cycle 3. Data was collected using the three aforementioned scales in addition with a questionnaire with demographic and clinical characteristics.
Results
The vast majority of patients were men (n = 42, 62.7%) and married ( 65.7 %, n = 44). Ten out of sixty-seven were multiple myeloma patients (n = 10, 14.9%). The mean scores of overall scales were: SF-36: 47.93±18.84, FACT-G: 73.68±18.25, EORTC-QLQ: 70,70±17.93. Cronbach’s a was >0.70 for all of the subscales of the questionnaires. There is an exception in emotional well being subscale of FACT-G and in physical functional subscale of EORTC QLQ-C30. Also, there was a strong correlation (>0.50) between physical functional subscale and emotional function subscale of the FACT-G, EORTC QLQ-C30 and SF-36 instruments (p < 0.001) and generally between the overall scores of three questionnaires (r = 0.771, p < 0.001 between FACT-G, EORTC QLQ-C30; r = 0.771, p < 0.001 between SF-36 and FACT-G; r = 0.842 p < 0.001 between SF-36 and EORTC QLQ-C30).
Conclusions
The Greek versions of FACT-G, EORTC QLQ-C30 and SF-36 questionnaires are valuable tools that could be easily applied in a daily practical routine for assessing quality of life in patients with hematological malignancies. Additionally, the above procedure provides valid information to the nursing staff in order to help their patients to improve their quality of life having possible influence in the disease outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract